id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-282504-m3npy0om	Kastritis, Efstathios	Challenges in the Management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic	2020-06-01		.txt	text/plain	4642	217	44	Patients with light chain (AL) amyloidosis have an underlying usually low-grade plasma or B-cell malignancy causing their disease, and they receive chemotherapy (Merlini, et al 2018) , thus, being at higher risk for infections (Kristinsson, et al 2012) , including from SARS-CoV-2, and probably at higher risk for severe COVID-19 (Pietrantonio and Garassino 2020) . Treatments for AL amyloidosis have not been developed in the context of multiple randomized studies, thus, we have limited data to propose one therapy over the other or assess the importance of full vs reduced dosing of critical drugs such as bortezomib or For selected patients who have achieved a satisfactory hematologic response (for example CR or VGPR or even PR with organ response), the treating physician may discuss to complete therapy earlier or continue with a less intensive schedule (for example reduce weekly to bi-weekly bortezomib).	./cache/cord-282504-m3npy0om.txt	./txt/cord-282504-m3npy0om.txt